GenWay and Beckman form biomarker discovery pact :
This article was originally published in Clinica
Executive Summary
GenWay Biotech is to provide Beckman Coulter with access to its method for enhancing the detection of biomarkers and drug targets, under an exclusive licensing deal formed between both parties. The method, IgY technology, selectively partitions the 12 most abundant proteins - up to 96% of the protein mass - from human serum or plasma. Because highly abundant plasma proteins are the main cause of assay noise, and may interfere with the detection of important biomarkers and drug targets, this technology could significantly facilitate the discovery of novel proteins, explained San Diego, California-based GenWay.